secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2025-01-02T23:59:59+00:00
Accession:  0001193125-25-000084
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neumora's Phase 3 KOASTAL-1 study of navacaprant fails primary endpoint in MDD
------------------------------------------------------------------------------

- Primary endpoint MADRS total score change at Week 6: -12.5 for both navacaprant and placebo (p=0.993); no statistical improvement.
- Key secondary endpoint SHAPS also missed: -5.8 vs -5.5 (p=0.648).
- Pre-specified subgroup analysis showed efficacy signal in females: MADRS LSMD -2.7 (p=0.072); SHAPS LSMD -2.3 (p=0.015).
- Navacaprant generally well-tolerated; no serious adverse events; discontinuation 2.1% vs 3.1% for placebo.
- Cash balance $342M provides runway into mid-2026; J.P. Morgan Healthcare Conference update planned Jan 14.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000119312525000084/0001193125-25-000084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000119312525000084/d859264d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-000084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer